| Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase. | |
| | |
MedLine Citation:
|
PMID: 10426846 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Angiographic thrombus is associated with increased coronary occlusion and restenosis rates after angioplasty. Administration of intracoronary urokinase decreases the incidence of thrombus but is associated with an increased periprocedural event rate, including stroke and myocardial infarction. An alternative approach is to deliver the agent directly into the arterial wall, thereby reducing the thrombotic substrate in the absence of a systemic effect of the delivered agent. OBJECTIVE: This randomized, double-blind, prospective study correlated intracardiac fibrinopeptide A levels with the ischemic events after angioplasty and evaluated whether locally administered urokinase could reduce the event rate. METHODS: Fifty-four patients with acute coronary syndromes were randomly assigned to local delivery of urokinase or saline. Levels of fibrinopeptide A, a marker of thrombin activity, were obtained before and after administration of heparin, after 2 balloon inflations, and at the end of the procedure in 43 patients and were correlated with ischemic events within the 6-month follow-up period (death, myocardial infarction, or recurrent ischemia). RESULTS: Multivariant analysis revealed that an elevated fibrinopeptide A level before angioplasty significantly correlated with an increased likelihood of an adverse event over the 6-month clinical follow-up. A postangioplasty reduction in the fibrinopeptide A level was noted in control patients (P <.001), but not after local urokinase administration, and the final fibrinopeptide A level was higher in the urokinase group (P =.02). Urokinase had no effect on the procedural results. On follow-up more patients receiving urokinase (13 of 27) had ischemic events than did control patients (6 of 25, P =.04). Most events were recurrent ischemia caused by restenosis. CONCLUSIONS: Heparin-resistant thrombin activity, as evidenced by an increased fibrinopeptide A level correlates with ischemic events on long-term follow-up. Local delivery of urokinase increased the event rate. |
| | |
Authors:
|
R L Wilensky; J M Pyles; N Fineberg |
Related Documents
:
|
6708976 - Dipyridamole-thallium-201 scintigraphy in the prediction of future cardiac events after... 8879456 - Predicting completeness of symptom relief after major heart surgery. 2214836 - Prediction of risk in noncardiac operations after cardiac operations. 9817266 - Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. 1385036 - Congestive heart failure: survival trial of antiarrhythmic therapy (chf stat). the chf ... 20460986 - Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing par... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: American heart journal Volume: 138 ISSN: 0002-8703 ISO Abbreviation: Am. Heart J. Publication Date: 1999 Aug |
Date Detail:
|
Created Date: 1999-08-26 Completed Date: 1999-08-26 Revised Date: 2006-02-27 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 319-25 Citation Subset: AIM; IM |
Affiliation:
|
Cardiovascular Division, University of Pennsylvania Medical Center, Philadelphia 19104, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angina, Unstable
/
therapy* Angioplasty, Transluminal, Percutaneous Coronary* Double-Blind Method Female Fibrinopeptide A / analysis* Humans Male Middle Aged Multivariate Analysis Myocardial Infarction / therapy* Pilot Projects Prospective Studies Recurrence |
| Chemical | |
Reg. No./Substance:
|
25422-31-5/Fibrinopeptide A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A new regimen for heparin use in acute coronary syndromes.
Next Document: Continued expansion of the nitinol self-expanding coronary stent: angiographic analysis and 1-year c...